EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Recent Pre-Clinical Advancements in Nuclear Medicine: Pioneering the Path to a Limitless Future

William Echavidre, Daniel Fagret, Marc Faraggi iD, Vincent Picco iD, Christopher Montemagno iD

Cancers · 03.10.2023 · 15 (19) · 4839

DOI: 10.3390/cancers15194839 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 03.10.2023. Verfasst von William Echavidre und 4 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Department, Centre Scientifique de Monaco, 98000 Monaco, Monaco. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 215 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Government of the Principality of Monaco, Foundation Flavien, GEMLUC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The theranostic approach in oncology holds significant importance in personalized medicine and stands as an exciting field of molecular medicine. Significant achievements have been made in this field in recent decades, particularly in treating neuroendocrine tumors using 177-Lu-radiolabeled somatostatin analogs and, more recently, in addressing prostate cancer through prostate-specific-membrane-antigen targeted radionuclide therapy. The promising clinical results obtained in these indications paved the way for the further development of this approach. With the continuous discovery of new molecular players in tumorigenesis, the development of novel radiopharmaceuticals, and the potential combination of theranostics agents with immunotherapy, nuclear medicine is poised for significant advancements. The strategy of theranostics in oncology can be categorized into (1) repurposing nuclear medicine agents for other indications, (2) improving existing radiopharmaceuticals, and (3) developing new theranostics agents for tumor-specific antigens. In this review, we provide an overview of theranostic development and shed light on its potential integration into combined treatment strategies.

Schlagwörter

Stichwörter der Autor:innen

immunotherapiesnuclear medicineoncologytheranostics

Autor:innen und Institutionen

  • Biomedical Department, Centre Scientifique de Monaco, 98000 Monaco, Monaco.
  • Laboratory of Bioclinical Radiopharmaceutics, Universite Grenoble Alpes, CHU Grenoble Alpes, Inserm, 38000 Grenoble, France.
  • Nuclear Medicine Department, Centre Hospitalier Princesse Grace, 98000 Monaco, Monaco.

ORCID-Profile: Marc Faraggi, Vincent Picco, Christopher Montemagno

Förderung

  • Government of the Principality of Monaco
  • Foundation Flavien
  • GEMLUC

Zitieren

APA

Echavidre, W., Fagret, D., Faraggi, M., Picco, V., & Montemagno, C. (2023). Recent Pre-Clinical Advancements in Nuclear Medicine: Pioneering the Path to a Limitless Future. Cancers, 15(19), 4839. https://doi.org/10.3390/cancers15194839

Vancouver

Echavidre W, Fagret D, Faraggi M, Picco V, Montemagno C. Recent Pre-Clinical Advancements in Nuclear Medicine: Pioneering the Path to a Limitless Future. Cancers. 2023;15(19):4839. doi:10.3390/cancers15194839

BibTeX
@article{Echavidre2023,
  author = {Echavidre, William and Fagret, Daniel and Faraggi, Marc and Picco, Vincent and Montemagno, Christopher},
  title = {Recent Pre-Clinical Advancements in Nuclear Medicine: Pioneering the Path to a Limitless Future},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {19},
  pages = {4839},
  doi = {10.3390/cancers15194839}
}
Kostenlos starten →